About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 879491, 5 pages
http://dx.doi.org/10.1155/2013/879491
Clinical Study

Infliximab Extends the Duration until the First Surgery in Patients with Crohn’s Disease

1Division of Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido 078-8510, Japan
2Division of Gastroenterological and General Surgery, Department of Surgery, Asahikawa Medical University, 2-1 Midorigaoka-higashi, Asahikawa, Hokkaido 078-8510, Japan
3Department of Gastroenterology, Sapporo Higashi Tokushukai Hospital, 3-1 North 33-jou East 14-chome East Ward, Sapporo, Hokkaido 065-0033, Japan

Received 16 July 2013; Revised 19 October 2013; Accepted 20 October 2013

Academic Editor: Hidekazu Kuramochi

Copyright © 2013 Aki Sakatani et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Bernell, A. Lapidus, and G. Hellers, “Risk factors for surgery and postoperative recurrence in Crohn's disease,” Annals of Surgery, vol. 231, no. 1, pp. 38–45, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. S. B. Hanauer, B. G. Feagan, G. R. Lichtenstein et al., “Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial,” The Lancet, vol. 359, no. 9317, pp. 1541–1549, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Rutgeerts, B. G. Feagan, G. R. Lichtenstein et al., “Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease,” Gastroenterology, vol. 126, no. 2, pp. 402–413, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. B. G. Feagan, R. Panaccione, W. J. Sandborn et al., “Effects ofadalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM Study,” Gastroenterology, vol. 135, no. 5, pp. 1493–1499, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J.-F. Colombel, W. J. Sandborn, P. Rutgeerts et al., “Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial,” Gastroenterology, vol. 132, no. 1, pp. 52–65, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. S. B. Hanauer, W. J. Sandborn, P. Rutgeerts et al., “Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial,” Gastroenterology, vol. 130, no. 2, pp. 323–332, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. G. R. Lichtenstein, S. Yan, M. Bala, M. Blank, and B. E. Sands, “Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease,” Gastroenterology, vol. 128, no. 4, pp. 862–869, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Schnitzler, H. Fidder, M. Ferrante et al., “Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort,” Gut, vol. 58, no. 4, pp. 492–500, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. K. Bhatia, B. I. Korelitz, G. Panagopoulos et al., “A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone,” Journal of Clinical Gastroenterology, vol. 41, no. 7, pp. 677–681, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Regueiro, W. Schraut, L. Baidoo et al., “Infliximab prevents Crohn's disease recurrence after ileal resection,” Gastroenterology, vol. 136, no. 2, pp. 441.e1–450.e1, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Dignass, G. Van Assche, J. O. Lindsay et al., “The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management,” Journal of Crohn's and Colitis, vol. 4, no. 1, pp. 28–62, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. G. D'Haens, F. Baert, G. van Assche et al., “Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial,” The Lancet, vol. 371, no. 9613, pp. 660–667, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. D. W. Jones and S. R. G. Finlayson, “Trends in surgery for crohn's disease in the era of infliximab,” Annals of Surgery, vol. 252, no. 2, pp. 307–312, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Domènech, Y. Zabana, E. Garcia-Planella et al., “Clinical outcome of newly diagnosed Crohn's disease: a comparative, retrospective study before and after infliximab availability,” Alimentary Pharmacology and Therapeutics, vol. 31, no. 2, pp. 233–239, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. S. C. Truelove and L. J. Witts, “Cortisone in ulcerative colitis; preliminary report on a therapeutic trial,” British Medical Journal, vol. 2, no. 4884, pp. 375–378, 1954. View at Scopus
  16. R. W. Summers, D. M. Switz, and J. T. Sessions Jr., “National cooperative Crohn's disease study: results of drug treatment,” Gastroenterology, vol. 77, no. 4, pp. 847–869, 1979. View at Scopus
  17. H. Malchow, K. Ewe, and J. W. Brandes, “European cooperative Crohn's disease study (ECCDS): results of drug treatment,” Gastroenterology, vol. 86, no. 2, pp. 249–266, 1984. View at Scopus
  18. G. R. Greenberg, B. G. Feagan, F. Martin et al., “Oral budesonide for active Crohn's disease,” The New England Journal of Medicine, vol. 331, no. 13, pp. 836–841, 1994. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Campieri, A. Ferguson, W. Doe, T. Persson, and L.-G. Nilsson, “Oral budesonide is as effective as oral prednisolone in active Crohn's disease,” Gut, vol. 41, no. 2, pp. 209–214, 1997. View at Scopus
  20. O. Ø. Thomsen, A. Cortot, D. Jewell et al., “A comparison of budesonide and mesalamine for active Crohn's disease,” The New England Journal of Medicine, vol. 339, no. 6, pp. 370–374, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. D. H. Present, B. I. Korelitz, and N. Wisch, “Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study,” The New England Journal of Medicine, vol. 302, no. 18, pp. 981–987, 1980. View at Scopus
  22. S. Candy, J. Wright, M. Gerber, G. Adams, M. Gerig, and R. Goodman, “A controlled double blind study of azathioprine in the management of Crohn's disease,” Gut, vol. 37, no. 5, pp. 674–678, 1995. View at Scopus
  23. J. F. Colombel, W. J. Sandborn, W. Reinisch et al., “Infliximab, azathioprine, or combination therapy for Crohn's disease,” The New England Journal of Medicine, vol. 362, no. 15, pp. 1383–1395, 2010. View at Publisher · View at Google Scholar · View at Scopus